• DNDi_Logo_No-Tagline_Full Colour
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Parasitic worms
      • Mycetoma
      • Dengue
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Pandemic preparedness
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Evidence for impact
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies and IP
      • Children’s health
      • Gender equity
      • Climate change
      • AI and new technologies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • Dengue Alliance
      • HAT Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
      • DNDi West and Central Africa
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
      • Podcasts, radio & TV
      • Media workshops
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • Our story
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
      • Our prizes and awards
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
  • DNDi_Logo_No-Tagline_Full Colour
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Parasitic worms
      • Mycetoma
      • Dengue
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Pandemic preparedness
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Evidence for impact
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies and IP
      • Children’s health
      • Gender equity
      • Climate change
      • AI and new technologies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • Dengue Alliance
      • HAT Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
      • DNDi West and Central Africa
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
      • Podcasts, radio & TV
      • Media workshops
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • Our story
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
      • Our prizes and awards
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
Home > News > New DNDi report: Open science in a closed world – lessons and opportunities for securing openness and equitable access in R&D collaborations  > Page 15

New DNDi report: Open science in a closed world – lessons and opportunities for securing openness and equitable access in R&D collaborations 

Home > News > New DNDi report: Open science in a closed world – lessons and opportunities for securing openness and equitable access in R&D collaborations  > Page 15

New DNDi report: Open science in a closed world – lessons and opportunities for securing openness and equitable access in R&D collaborations 

Geneva, Switzerland — 17 Nov 2025

The Drugs for Neglected Diseases initiative (DNDi) is pleased to announce the publication of its new policy report, Open science in a closed world – lessons and opportunities for securing openness and equitable access in R&D collaborations. 

Building on DNDi’s more than 20 years of experience developing treatments for neglected populations, the report explores how open and collaborative science, including a pro-access approach to managing intellectual property, can accelerate innovation, promote knowledge sharing, and ensure that life-saving health technologies are affordable and accessible to all who need them. 

The report provides one of the first comprehensive looks at how openness can be operationalized in real-world R&D collaborations. In particular, it examines: 

  • The tensions and trade-offs between open science and more traditional, proprietary biomedical research models; 
  • DNDi’s continuum of open science approaches, ranging from bilateral partnerships with industry to more open-source collaborations such as the Open Synthesis Network and the COVID-19 Moonshot; 
  • Case studies exploring how open science approaches were navigated in specific DNDi projects and partnerships; 
  • A practical framework for embedding openness and equitable access across the innovation lifecycle based on DNDi’s experience; and 
  • Actionable recommendations for governments, R&D funders, academia and other research organizations, and industry to operationalize openness and equity in their innovation policies, practices, and partnerships. 

And it comes at a critical time: on the one hand, major funding cuts to medical research and growing geopolitical tensions are threatening fragile gains in global health. On the other hand, there are potentially transformative technological advances in biomedicine, renewed calls for stronger and more self-sufficient innovation ecosystems, especially in low- and middle-income countries, and an emerging consensus, including in the Pandemic Agreement, about how governments can leverage the power of public R&D funding to shape health innovation outcomes so that greater openness and equitable access are ensured. 

Open science in a closed world makes the case that research knowledge should be viewed not as a commodity to be enclosed, but as a shared resource essential to achieving more equitable health outcomes and argues that greater openness must move from aspiration to implementation—making open sharing of knowledge, data, and know-how as well as equitable access core objectives of R&D. 

DNDi invites policymakers, funders, researchers, and advocates to join the discussion and help translate the report’s recommendations into concrete action. 

  • READ THE REPORT
    • English
    • Português

Join the conversation: Share your reflections on social media!

access the toolkit

Photo credit: Thoko Chikondi-DNDi

Policy advocacy

Read, watch, share

Loading...
Publications
24 Sep 2024

HAT Platform Newsletter No. 23

Healthcare worker with patient in hospital setting
Publications
19 Sep 2024

InfoLEISH 8th edition

Healthcare worker with a woman in hospital setting
Publications
19 Sep 2024

Chagas Platform Newsletter N°14

Alwyn Mwinga
News
6 Sep 2024

Message on the passing of Dr Alwyn Mwinga from DNDi Executive Director Dr Luis Pizarro

Stories
2 Sep 2024

From Ituri to Geneva, in the search for new medicines for river blindness

PKDL study infographic
Publications
17 Jul 2024

The Science Explained: Good news for people living with PKDL in Eastern Africa

Young woman in rural setting
Press releases
17 Jul 2024

Clinical trial in Eastern Africa finds a shorter, safer, and more effective treatment for PKDL, a stigmatizing skin disease

Publications
11 Jul 2024

DNDi 2023 Annual Report

VIEW ALL

Help neglected patients

To date, we have delivered fourteen new treatments, saving millions of lives.

Our goal is to deliver 25 new treatments in our first 25 years. You can help us get there. 

GIVE NOW
Linkedin-in Instagram Youtube X-twitter Tiktok Facebook-f
International non-profit developing safe, effective, and affordable treatments for the most neglected patients.

Learn more

  • Diseases
  • Neglected tropical diseases
  • R&D portfolio
  • Policy advocacy

Get in touch

  • Our offices
  • Contact us
  • Integrity Line

Support us

  • Donate
  • Subscribe to eNews

Work with us

  • Join research networks
  • Jobs
  • RFPs
  • Terms of Use   
  •   Acceptable Use Policy   
  •   Privacy Policy   
  •   Cookie Policy   
  •   Our policies   

  • Except for images, films, and trademarks which are subject to DNDi’s Terms of Use, content on this site is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International license